ZA892877B - Azelastine-containing medicaments with controlled release of the active substance - Google Patents

Azelastine-containing medicaments with controlled release of the active substance

Info

Publication number
ZA892877B
ZA892877B ZA892877A ZA892877A ZA892877B ZA 892877 B ZA892877 B ZA 892877B ZA 892877 A ZA892877 A ZA 892877A ZA 892877 A ZA892877 A ZA 892877A ZA 892877 B ZA892877 B ZA 892877B
Authority
ZA
South Africa
Prior art keywords
azelastine
active substance
controlled release
release
containing medicaments
Prior art date
Application number
ZA892877A
Other languages
English (en)
Inventor
Helmut Hettche
Hettche Helmut
Original Assignee
Asta Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Pharma Ag filed Critical Asta Pharma Ag
Publication of ZA892877B publication Critical patent/ZA892877B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Switches With Compound Operations (AREA)
  • Polyurethanes Or Polyureas (AREA)
  • Rotary Pumps (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ZA892877A 1988-04-20 1989-04-19 Azelastine-containing medicaments with controlled release of the active substance ZA892877B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3813244 1988-04-20

Publications (1)

Publication Number Publication Date
ZA892877B true ZA892877B (en) 1989-12-27

Family

ID=6352451

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA892877A ZA892877B (en) 1988-04-20 1989-04-19 Azelastine-containing medicaments with controlled release of the active substance

Country Status (15)

Country Link
EP (1) EP0338444B1 (da)
JP (1) JP2950845B2 (da)
AT (1) ATE97572T1 (da)
AU (1) AU3318389A (da)
CA (1) CA1325976C (da)
DE (1) DE58906232D1 (da)
DK (1) DK172235B1 (da)
ES (1) ES2060685T3 (da)
FI (1) FI891865L (da)
HK (1) HK134494A (da)
HU (1) HU202403B (da)
IE (1) IE62778B1 (da)
MC (1) MC2025A1 (da)
PT (1) PT90308B (da)
ZA (1) ZA892877B (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9003903D0 (sv) * 1990-12-07 1990-12-07 Astra Ab New pharmaceutical formulations
DE4207234A1 (de) * 1992-03-07 1993-09-09 Asta Medica Ag Neue aminocarbonsaeure-derivate mit antiallergischer/antiasthmatischer wirkung und verfahren zu deren herstellung
JPH0710747A (ja) * 1993-04-28 1995-01-13 Takeda Chem Ind Ltd 固形製剤およびその製造方法
GB9514842D0 (en) * 1995-07-20 1995-09-20 Smithkline Beecham Plc Novel formulation
JP4138910B2 (ja) 1997-07-02 2008-08-27 帝國製薬株式会社 経皮吸収性が良好で且つ皮膚刺激性の少ない塩酸アゼラスチン含有経皮製剤
UA67802C2 (uk) * 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
IL142896A0 (en) 1998-11-02 2002-04-21 Elan Corp Plc Multiparticulate modified release composition
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
EP2295043A1 (en) 1999-10-29 2011-03-16 Euro-Celtique S.A. Controlled release hydrocodone formulations
AU2002227383B2 (en) 2000-10-30 2004-07-08 Euro-Celtique S.A. Controlled release hydrocodone formulations
EP1396263A1 (en) * 2002-08-09 2004-03-10 Warner-Lambert Company Film coating for tablets and caplets
CA2510319A1 (en) 2002-12-20 2004-07-15 Thomas J. Smith High pressure compaction for pharmaceutical formulations
PL2486942T3 (pl) * 2004-11-24 2019-05-31 Meda Pharmaceuticals Inc Kompozycje zawierające azelastynę oraz sposoby ich stosowania
CN110575445B (zh) 2013-03-21 2023-08-18 优普顺药物公司美国分部 可注射的持续释放组合物及其用于治疗关节炎症及相关疼痛的方法
AU2016343952A1 (en) 2015-10-27 2018-05-10 Eupraxia Pharmaceuticals Inc. Sustained release formulations of local anesthetics

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE49205T1 (de) * 1984-09-14 1990-01-15 Asta Pharma Ag Substituierte benzylphthalazinon-derivate.

Also Published As

Publication number Publication date
MC2025A1 (fr) 1990-04-25
PT90308A (pt) 1989-11-10
AU3318389A (en) 1989-10-26
ES2060685T3 (es) 1994-12-01
IE62778B1 (en) 1995-02-22
ATE97572T1 (de) 1993-12-15
DK189189A (da) 1989-10-21
FI891865A7 (fi) 1989-10-21
JPH01311024A (ja) 1989-12-15
FI891865L (fi) 1989-10-21
DK172235B1 (da) 1998-02-02
JP2950845B2 (ja) 1999-09-20
EP0338444A1 (de) 1989-10-25
DK189189D0 (da) 1989-04-19
FI891865A0 (fi) 1989-04-19
CA1325976C (en) 1994-01-11
HUT49808A (en) 1989-11-28
DE58906232D1 (de) 1994-01-05
HU202403B (en) 1991-03-28
PT90308B (pt) 1994-10-31
HK134494A (en) 1994-12-09
IE891263L (en) 1989-10-20
EP0338444B1 (de) 1993-11-24

Similar Documents

Publication Publication Date Title
PT615754E (pt) Formas solidas de administracao oral de libertacao controlada flupertina
GR3007202T3 (da)
IL85523A (en) Stable alpha interferon complex,its preparation and pharmaceutical compositions comprising it
IL95691A0 (en) Thienylcarboxylates of amino alcohols,their preparation and pharmaceutical compositions containing them
EP0427247A3 (en) Pharmaceutical composition with r-alpha-lipoic acid or s-alpha-lipoic acid as the active ingredient
AU3318389A (en) Azelastine-containing medicaments with controlled release of the active substance
ATE76747T1 (de) Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.
IL80149A (en) Pharmaceutical compositions containing toluidide derivatives against graft-versus-host diseases and autoimmune diseases
GR3017367T3 (en) composition in the form of a foam containing 5-aminosalicylic acid for intra-rectal administration.
TW355683B (en) Composition containing micronized nebivolol
ZA928170B (en) Antiviral 4-substituted-2-deoxy-2,3-didehydro-derivatives of alpha-D-neuraminic acid
PT85829A (en) Therapeutic agents
FI885460L (fi) Menetelmä suun kautta annettavaksi tarkoitetun, aktiiviyhdistettä kontrolloidusti vapauttavan farmaseuttisen formulaation valmistamiseksi
DE3766200D1 (de) L-dopa enthaltendes arzneimittel.
GR3006091T3 (da)
DK0458588T3 (da) Behandling af okulær hypertension med en synergistisk kombination til okulær administration
GR890100833A (en) Process for the preparation of a compound with gastric inhibitopy effect
ZA881053B (en) Prostaglandin e1 derivatives as pharmacologically active agents,and pharmaceutical compositions containing these compounds,especially for transcutaneous administration
HUT50787A (en) Process for producing pharmaceutical compositions comprising 4-aryl-4-piperidine-, pyrrolidine- or hexahydroazepincarbinol derivatives or heterocyclic analogs thereof as active ingredient and process for producing the new compounds
GR3002765T3 (en) New pharmaceutical compositions for parenteral use containing a calcitonin as the active ingredient
EP0380989A3 (en) Plaster for transdermal administration
EP0351876A3 (en) Composition for potentiating vaccination effect
ATE85218T1 (de) Oral anzuwendende arzneiform zur einmal taeglichen behandlung der hypertonie mit diltiazemhydrochlorid.
EP0335446A3 (en) Agents for treating neoplasms
ES2051864T3 (es) Un procedimiento para preparar una composicion farmaceutica con actividad anti-cancer.